ArticleOncogene2007
MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia.
Article in Oncogene, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 180 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
180 citing papers in PubMed, 2 syntheses or guidelines pooled it, 361 citations in OpenAlex.
- Modulation of all-trans retinoic acid-induced MiRNA expression in neoplastic cell lines: a systematic review.BMC cancer · 2019Pooled it
- Prognostic value of meta-signature miRNAs in renal cell carcinoma: an integrated miRNA expression profiling analysis.Scientific reports · 2015Pooled it
- Lycopene, Carotenoids, and Retinoids in Cancer Chemoprevention: Molecular Mechanisms and Clinical Implications.Nutrients · 2026Review
- Integrative miRNA-mRNA Network and Molecular Dynamics-Based Identification of Therapeutic Candidates for Paroxysmal Nocturnal Hemoglobinuria.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Plasma exosomal miR-122-5p_R-1, miR-23b-3p_R + 1, and miR-15a-5p_R-1 are associated with multidrug-resistant tuberculosis.BMC infectious diseases · 2025Article
- Emerging biologic and clinical implications of miR-182-5p in gynecologic cancers.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- Harnessing the power of exosomes for diagnosis, prognosis, and treatment of hematological malignancies.Stem cell research & therapy · 2025Review
- MiR-223-3p in Cancer Development and Cancer Drug Resistance: Same Coin, Different Faces.International journal of molecular sciences · 2024Review
- K-Homology Type Splicing Regulatory Protein: Mechanism of Action in Cancer and Immune Disorders.Critical reviews in eukaryotic gene expression · 2024Article
- miR-603 promotes cell proliferation and differentiation by targeting TrkB in acute promyelocytic leukemia.Annals of hematology · 2023Article
- Insight into microRNAs' involvement in hematopoiesis: current standing point of findings.Stem cell research & therapy · 2023Review
- MicroRNA-223 limits murine hemogenic endothelial cell specification and myelopoiesis.Developmental cell · 2023Article
- High expression of miR-107 and miR-17 predicts poor prognosis and guides treatment selection in acute myeloid leukemia.Translational cancer research · 2023Article
- Small noncoding RNAs play superior roles in maintaining hematopoietic stem cell homeostasis.Blood science (Baltimore, Md.) · 2022Article
- Immunomodulation by Bifidobacterium animalis subsp. lactis Bb12: Integrative Analysis of miRNA Expression and TLR2 Pathway-Related Target Proteins in Swine Monocytes.Probiotics and antimicrobial proteins · 2022Article
- Effect of microRNA-181b on the biological characteristics and clinical drug resistance of small-cell lung cancer by targeting angiotensin converting enzyme 2.Thoracic cancer · 2022Article
- Machine Learning Based Methods and Best Practices of microRNA-Target Prediction and Validation.Advances in experimental medicine and biology · 2022Article
- Potential Molecular Mechanisms of Recurrent and Progressive Meningiomas: A Review of the Latest Literature.Frontiers in oncology · 2022Review
- Clinical Value of Serum miRNA in Patients with Acute Promyelocytic Leukemia.Journal of oncology · 2022Article
- Article
120 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
14 authors at 3 institutions in 2 countries.
Funding
Abstract
MicroRNAs (miRNAs) are small non-coding RNAs of 19-25 nucleotides that are involved in the regulation of critical cell processes such as apoptosis, cell proliferation and differentiation. However, little is known about the role of miRNAs in granulopoiesis. Here, we report the expression of miRNAs in acute promyelocytic leukemia patients and cell lines during all-trans-retinoic acid (ATRA) treatment by using a miRNA microarrays platform and quantitative real time-polymerase chain reaction (qRT-PCR). We found upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342 and miR-107, whereas miR-181b was downregulated. Among the upregulated miRNAs, miR-107 is predicted to target NFI-A, a gene that has been involved in a regulatory loop involving miR-223 and C/EBPa during granulocytic differentiation. Indeed, we have confirmed that miR-107 targets NF1-A. To get insights about ATRA regulation of miRNAs, we searched for ATRA-modulated transcription factors binding sites in the upstream genomic region of the let-7a-3/let-7b cluster and identified several putative nuclear factor-kappa B (NF-kappaB) consensus elements. The use of reporter gene assays, chromatin immunoprecipitation and site-directed mutagenesis revealed that one proximal NF-kappaB binding site is essential for the transactivation of the let-7a-3/let-7b cluster. Finally, we show that ATRA downregulation of RAS and Bcl2 correlate with the activation of known miRNA regulators of those proteins, let-7a and miR-15a/miR-16-1, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.